TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00301184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pGA2/JS7 DNA
Description: DNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pGA2/JS7 DNA
Description: DNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pGA2/JS7 DNA
Description: DNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified vaccinia Ankara/HIV62
Description: Recombinant Modified Ankara Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified vaccinia Ankara/HIV62
Description: Recombinant Modified Ankara Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified vaccinia Ankara/HIV62
Description: Recombinant Modified Ankara Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified vaccinia Ankara/HIV62
Description: Recombinant Modified Ankara Vaccine
Study: NCT03599232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formative objective structured clinical examination (OSCE)
Study: NCT02265159

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Focal Therapy Using High Intensity Focused Ultrasound
Study: NCT03945292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fazisiran Injection
Description: solution for subcutaneous (sc) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fazisiran Injection
Description: solution for subcutaneous (sc) injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection
Study: NCT03741595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Item spacing
Description: Spatial proximity of items to one another
Study: NCT03830125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-877, Single dose
Description: Single dose of BBT-877, 5 dose levels, oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo group
Description: Placebo matched to BBT-877, oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo group
Description: Placebo matched to BBT-877, oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-877, Multiple doses
Description: Multiple doses of BBT-877, 14 days, 8 dose levels, oral capsule
Study: NCT02885077

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High-intensity IMT + combined exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity IMT + combined exercise
Study: NCT04193072

Intervention type: BEHAVIORAL
Intervention: Assessment of imagery ability
Description: Movement imagery, kinesthetic imagery, and visual imagery ability assessed.

Intervention type: BEHAVIORAL
Intervention: Assessment of imagery ability
Description: Movement imagery, kinesthetic imagery, and visual imagery ability assessed.
Study: NCT03007251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eurythmy Therapy Movement R

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eurythmy Therapy Movement L

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eurythmy Therapy Movement B

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal movements during walking or standing
Study: NCT01539044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine, atropine
Description: 0.05 mg/KG NEOSTIGMINE AND 0.02 MG/ KG ATROPINE at TOF 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: 4 mg/kg sugammadex will be given stat at the end of surgery at PTC 1-2
Study: NCT02785796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CV4

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SHAM TECHNIQUE
Study: NCT04610281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inner Garden
Description: Care actions adapted to the intensity of the states of agitation (The child can be removed from the group while remaining in the same room on a chair with a caregiver. If the problems are too serious, the child can be accompanied to a soothing room where the carer will take care of him/her individually. In units equipped with Inner Garden, the child can use it under semi- supervision of nurses.)
Study: NCT02381483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Study: NCT04884464

Intervention type: DEVICE
Intervention: Hyaluronic acid-based gel
Description: Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks

Intervention type: DRUG
Intervention: Chlorhexidine Gluconate
Description: Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
Study: NCT02736890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A
Description: Subjects will receive subcutaneous Botulinum Toxin A injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive subcutaneous placebo injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
Study: NCT03336437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol vaginal ring
Description: Estradiol 2mg vaginal ring

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal ring
Description: Silicone vaginal ring without any active estradiol
Study: NCT00995293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CISPLATIN
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CISPLATIN
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FLUOROURACIL
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FLUOROURACIL
Description: Intravenous
Study: NCT03847506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Rosuvastatin
Description: Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Candesartan cilexetil 8 mg placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil/Amlodipine besylate
Description: Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Ezetimibe/Rosuvastatin 10 mg/10 mg placebo + Candesartan cilexetil 8 mg placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg placebo
Study: NCT01504906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Oral tablets, 600 mg , single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Oral tablets, 600 mg , single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Oral tablets, 180 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Oral tablets, 180 mg, single dose
Study: NCT03112083

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling A
Description: Krill powder capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional counselling B
Description: Placebo capsules
Study: NCT03181737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Covivio/Relaxio
Description: Informations already included in arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Covivio/Relaxio
Description: Informations already included in arm/group descriptions.
Study: NCT03408704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASP
Description: It consists of one educational session where doctors and staff at the center discuss current guidelines around management of patients attending for a sore throat. At the education the following is discussed:~1. The Swedish guidelines~2. Example of cases~3. Statistics from previous 6 month showing how well this clinic adheres to the Swedish guidelines.
Study: NCT02059096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)

Intervention type: DEVICE
Group type: OTHER
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)

Intervention type: DEVICE
Group type: OTHER
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Study: NCT01504646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lyprinol
Description: 8 capsules (1 capsule=50mg n-PUFA, 100mg olive oil) per day for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Olive Oil)
Description: 8 capsules (1 capsule = 100mg olive oil) per day for 3 weeks
Study: NCT02299583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventive intervention trauma-informed early intervention
Description: Every department appoints 2-4 health care professionals as child welfare officers (CWOs) who will be responsible for carrying out the intervention at the department. Whenever a child or adolescent is present in the department a CWO will be send for. The intervention consists of four distinct elements: 1) A standardized plan of action for the appointed health care CWOs on how to conduct trauma-informed health care for children and their families shortly after exposure to a PTE, 2) a training program for CWOs on trauma-informed support and communication with children and their families, 3) a supervision program for the CWOs, and 4) three psychoeducational booklets for young children, older children, and parents. The booklets will be given to the families by the CWOs.
Study: NCT03539549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abicipar pegol
Description: Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
Study: NCT03303508

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: anti-ds DNA
Description: venous blood samples
Study: NCT01623713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloperidone
Description: Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.
Study: NCT00475306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide 10 mg
Description: an anti-emetic medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide 10 mg
Description: an anti-emetic medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine 25 mg
Description: used for prophylaxis against akathisia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine 25 mg
Description: used for prophylaxis against akathisia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02121366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided ethanol ablation
Description: Diagnostic evaluation for suspected insulinoma is performed by cytology or immunohistochemistry. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol under the guidance of EUS was injected into the lesion. The amount of ethanol is administrated according to the size of lesion.
Study: NCT00475306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 20 mg
Description: Metoclopramide 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 20 mg
Description: Metoclopramide 20 mg
Study: NCT01660074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test food
Description: All food, include reference food was tested in 50g available carbohydrate portion size.
Study: NCT03778112

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT to whole prostate
Description: Those patients with negative mpMRI prostate scan (PI-RADS 0-2) will receive SBRT (36.25 Gy/5 fractions) to the whole prostate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT followed by mpMRI guided SBRT boost with SIB to intraprostatic lesions
Description: Patients with positive or equivocal mpMRI prostate scan (PI-RADS 3-5) will receive IMRT (45 Gy/25 fractions) to the prostate + seminal vesicles +/- lymph nodes followed by SBRT boost (18 Gy/3 fractions) to the whole prostate with simultaneous integrated boost (21 Gy/3 fractions) to MRI defined intraprostatic lesions
Study: NCT02163434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Study: NCT04378803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) Connect
Description: MT Connect will involve instructor-led weekly sessions and mindfulness exercises over a 4-week interval for a total of 8 to 10 hours. There will be one instructor-led session per week that will last between 2 and 2.5 hours. Participants will also be asked to complete three categories of mindfulness exercises (formal and informal mindfulness exercises, and reflective practices) as part of their daily 'out-of-class' homework. The daily homework will require between 10 to 30 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) Connect
Description: MT Connect will involve instructor-led weekly sessions and mindfulness exercises over a 4-week interval for a total of 8 to 10 hours. There will be one instructor-led session per week that will last between 2 and 2.5 hours. Participants will also be asked to complete three categories of mindfulness exercises (formal and informal mindfulness exercises, and reflective practices) as part of their daily 'out-of-class' homework. The daily homework will require between 10 to 30 minutes to complete.
Study: NCT02230670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Description: 25 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02967341

Intervention type: OTHER
Group type: OTHER
Intervention: Ciprofloxacin administration
Description: Ciprofloxacin will be administered via the PAC directly followed by a NaCl 0.9% flush to wash the PAC. At least 1 hour afterwards 500 microliter of blood will be drawn via the PAC. Directly hereafter a blood draw of 500 microliter will be performed either via capillary blood sampling or via a venipuncture. If an anaesthesia is foreseen for another procedure (e.g. a lumbar puncture or an osseous punction), we will strive to perform the peripheral blood draw under anaesthesia.
Study: NCT02078960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine mepesuccinate
Description: 3.5 mg omacetaxine mepesuccinate and 10 mg mannitol; The first dose of the day for cycle 1 will be administered at the investigational center. Subsequent doses (in prefilled syringes) may be administered on an outpatient basis after training takes place
Study: NCT03289624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHARE-CC
Description: Each of the 6 SHARE-CC sessions are structured similarly, starting with the dyad reviewing goals of the session, the CG \& PWCC meeting jointly or separately with the SHARE-CC Counselor around session-specific material, \& ending with a review of material, addressing questions, \& previewing the next session. Sessions titles are: Communication \& Health Education; Care Values; Care Preferences; Family, Friends, \& Community Resources; Taking care of yourself-taking care of each other; \& Take Action Now.~The SHARE plan will be developed throughout the sessions and reflects the consensus achieved because of participating in SHARE-CC. It is intended to ensure that the PWCC's values \& preferences are supported when decisions have to be in the future.
Study: NCT01373541

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: InFat™ based infant formula
Description: high sn-2 palmitic acid oil based infant formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard vegetable oil based infant formula
Description: standard vegetable oil based infant formula
Study: NCT04249349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assisted gait with a motorized ankle foot orthosis
Description: The motorized ankle foot orthosis is a powered lower extremity assistance device with an actuated ankle joint. A novel control software has been design and implemented in this device, which allows precise joint movement and recording of data from training session.
Study: NCT01523275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin -C
Description: Topical mitomycin-C at a dosage of 0.4mg/ml will be applied to cottonoid pledgets and placed into the radial incisions for 3 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline application
Description: Isotonic saline will be applied to cottonoid pledgets and placed into the patient's radial incisions for 3 minutes as the placebo intervention.
Study: NCT02250729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intradermal pholcodine allergy test in cases

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Study: NCT02536417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: To determine the effectiveness of melatonin in preventing the development of delirium compared with placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: To determine if placebo effect plays a part in preventing the development of delirium
Study: NCT00905645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silimed Gel-Filled Mammary Implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silimed Gel-Filled Mammary Implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silimed Gel-Filled Mammary Implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silimed Gel-Filled Mammary Implant
Study: NCT01785992

Intervention type: DRUG
Group type: OTHER
Intervention: Irosustat
Description: Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or development of unacceptable toxicities.
Study: NCT04170985

Intervention type: OTHER
Intervention: clinical Whole Genome Sequencing
Description: Participants will receive cWGS as well as standard of care testing. The clinician/site PI will be blinded to the cWGS results until Day 180.
Study: NCT01743859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Off Therapy
Description: 2 weeks off therapy, then begin sequence again for 12 weeks.
Study: NCT03301116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Moves for Aging Well (Healthy Moves)
Description: A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position. The intervention will be delivered by home care aides for their clients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Mind for Aging Well (Active Mind)
Description: A word puzzle program which consists of a brief motivational enhancement and word search activities. The intervention will be delivered by home care aides for their clients.
Study: NCT01124487

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The acute effects of dietary fat on lipid profile, insulin sensitivity and inflammatory markers

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The acute effects of dietary fat on lipid profile, insulin sensitivity and inflammatory markers

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The acute effects of dietary fat on lipid profile, insulin sensitivity and inflammatory markers
Study: NCT00168831

Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium Inhalation Solution

Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium Inhalation Solution

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study: NCT00741845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravaginal metronidazole
Description: high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravaginal metronidazole
Description: high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravaginal metronidazole
Description: high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg
Study: NCT02862756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diffusion-weighted MRI and clinical examination
Study: NCT04657666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Description: oromucosal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oromucosal spray